The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years’ experience of association studies to understand the genetic architecture of pancreatic cancer
Daniele Campa, Manuel Gentiluomo, Angelika Stein, Mateus Nóbrega Aoki, Martin Oliverius, Ľudmila Vodičková, Krzysztof Jamroziak, George Theodoropoulos, Claudio Pasquali, William Greenhalf, Paolo Giorgio Arcidiacono, Faik G. Uzunoǧlu, Raffaele Pezzilli, Claudio Luchini, Marta Puzzono, Martin Loos, Matteo Giaccherini, Verena Katzke, Andrea Mambrini, Edita Kiudeliene, Kauffmann Emanuele Federico, Julia S. Johansen, Tamás Hussein, Beatrice Mohelníková-Duchoňová, Casper H.J. van Eijck, Hermann Brenner, Riccardo Farinella, Juan Sáinz Pérez, Martin Loveček, Markus W. Büchler, Viktor Hlaváč, Jakob R. Izbicki, Thilo Hackert, Roger Chammas, Alessandro Zerbi, Rita T. Lawlor, Alessio Felici, M Götz, Gabriele Capurso, Laura Ginocchi, Maria Gazouli, Juozas Kupčinskas, Giulia Martina Cavestro, Pavel Vodička, Stefania Moz, John P. Neoptolemos, Lumír Kunovský, Stig E. Bojesen, Silvia Carrara, Domenica Gioffreda, Egidijus Morkūnas, Olga Abián, Ștefania Bunduc, Daniela Basso, Ugo Boggi, Barbara Włodarczyk, Andrea Szentesi, Giuseppe Vanella, Inna M. Chen, Maarten F. Bijlsma, Vytautas Kiudelis, Stefano Landi, Ben Schöttker, Chiara Corradi, Nathalia A. Giese, Rudolf Kaaks, Giulia Peduzzi, Péter Hegyi, Luca Morelli, Niccolò Furbetta, Pavel Souček, Anna Latiano, Renata Talar‐Wojnarowska, Sidsel C. Lindgaard, Frederike Dijk, Anna Caterina Milanetto, Francesca Tavano, Klára Červená, Bálint Erőss, Sabrina Gloria Giulia Testoni, Judith H.E. Verhagen-Oldenampsen, Ewa Małecka-Wojciesko, Eithne Costello, Roberto Salvia, Evaristo Maiello, Stefano Ermini, Cosimo Sperti, Bernd Holleczek, Francesco Perri, Jurgita Skiecevičienė, Lívia Archibugi, M Lucchesi, Cosmeri Rizzato, Federico Canzian
Abstract
Pancreatic cancer has an incidence that almost matches its mortality. Only a small number of risk factors and 33 susceptibility loci have been identified. so Moreover, the relative rarity of pancreatic cancer poses significant hurdles for research aimed at increasing our knowledge of the genetic mechanisms contributing to the disease. Additionally, the inability to adequately power research questions prevents small monocentric studies from being successful. Several consortia have been established to pursue a better understanding of the genetic architecture of pancreatic cancers. The Pancreatic disease research (PANDoRA) consortium is the largest in Europe. PANDoRA is spread across 12 European countries, Brazil and Japan, bringing together 29 basic and clinical research groups. In the last ten years, PANDoRA has contributed to the discovery of 25 susceptibility loci, a feat that will be instrumental in stratifying the population by risk and optimizing preventive strategies. • Thirty-three pancreatic cancer susceptibility loci have been discovered so far. • Polygenic risk scores are a powerful tool to stratify the population into low and high risk individuals. • Secondary analyses on existing GWAS data have identified three susceptibility loci.